Stoke Therapeutics shares STK-002 data for eye disorder at AAO

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to Stoke Therapeutics shares STK-002 data for eye disorder at AAO

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

October 12, 2026 8:00 AM EDT

ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision loss

STK-002 represents a novel approach to ADOA by targeting the underlying disease biology, with the potential to be the first disease-modifying medicine for people living with ADOA

ADOA natural history findings and preclinical proof-of-concept data for STK-002 support the ongoing Phase 1 OSPREY study in people with ADOA

Dosing is now... More